Ikarian Capital’s Rein Therapeutics RNTX Stock Holding History

Ikarian Capital’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.07M	Buy	+2,950,000	New	+$3.57M	0.33%	74
2022 Q3	–	Sell	-144,616	Closed	-$752K	–	165
2022 Q2	$752K	Sell	144,616 -488	-0.3%	-$4.48K	0.14%	90
2022 Q1	$1.49M	Buy	145,104 +6,925	+5%	+$62.7K	0.2%	82
2021 Q4	$1.56M	Hold	138,179	–	–	0.23%	80
2021 Q3	$2.82M	Sell	138,179 -1,821	-1%	-$39.9K	0.2%	110
2021 Q2	$3.5M	Hold	140,000	–	–	0.28%	85
2021 Q1	$4M	Buy	+140,000	New	+$4.8M	0.13%	140

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Ikarian Capital's RNTX Position: Q2 2026 in Review

Ikarian Capital opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 2,950,000 shares worth $3.07M. The stake represents 0.33% of the portfolio and ranks #74 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in RNTX as recently as Q2 2022.

Ikarian Capital first reported a position in RNTX in Q1 2021 and has held it in 7 quarters since. The position peaked at $4M in Q1 2021. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Ikarian Capital held 2,950,000 shares of Rein Therapeutics worth $3.07M as of Q2 2026.
Rein Therapeutics was a new Ikarian Capital position in Q2 2026.
Rein Therapeutics made up 0.33% of Ikarian Capital's portfolio in Q2 2026, its #74 holding.
Ikarian Capital first reported a position in Rein Therapeutics in Q1 2021 and has held it in 7 quarters since.
Ikarian Capital's Rein Therapeutics position peaked at $4M in Q1 2021.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.